Astria Therapeutics Analyst Ratings
Astria Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 433.05% | Oppenheimer | $30 → $25 | Maintains | Outperform |
| 10/13/2023 | 283.8% | Wedbush | $25 → $18 | Maintains | Outperform |
| 10/12/2023 | 283.8% | HC Wainwright & Co. | $20 → $18 | Maintains | Buy |
| 08/08/2023 | 433.05% | Wedbush | $26 → $25 | Maintains | Outperform |
| 08/08/2023 | 326.44% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 06/08/2023 | 539.66% | Oppenheimer | → $30 | Reiterates | Outperform → Outperform |
| 05/12/2023 | 454.37% | Wedbush | → $26 | Reiterates | → Outperform |
| 05/12/2023 | 326.44% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 03/28/2023 | 283.8% | Evercore ISI Group | → $18 | Initiates Coverage On | → Outperform |
| 02/24/2023 | 326.44% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 12/19/2022 | 326.44% | HC Wainwright & Co. | $13 → $20 | Maintains | Buy |
| 09/29/2021 | 326.44% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/15/2023 | 433.05% | 奥本海默 | 30 美元 → 25 美元 | 维护 | 跑赢大盘 |
| 10/13/2023 | 283.8% | Wedbush | 25 美元 → 18 美元 | 维护 | 跑赢大盘 |
| 2023 年 12 月 10 日 | 283.8% | HC Wainwright & Co. | 20 美元 → 18 美元 | 维护 | 买 |
| 08/08/2023 | 433.05% | Wedbush | 26 美元 → 25 美元 | 维护 | 跑赢大盘 |
| 08/08/2023 | 326.44% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 06/08/2023 | 539.66% | 奥本海默 | → 30 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 05/12/2023 | 454.37% | Wedbush | → 26 美元 | 重申 | → 跑赢大盘 |
| 05/12/2023 | 326.44% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 03/28/2023 | 283.8% | Evercore ISI 集团 | → 18 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 02/24/2023 | 326.44% | HC Wainwright & Co. | → 20 美元 | 重申 | → 购买 |
| 2022 年 12 月 19 日 | 326.44% | HC Wainwright & Co. | 13 美元 → 20 美元 | 维护 | 买 |
| 09/29/2021 | 326.44% | 杰富瑞集团 | → 20 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Astria Therapeutics (ATXS)?
Astria Therapeutics（ATXS）的目标价格是多少？
The latest price target for Astria Therapeutics (NASDAQ: ATXS) was reported by Oppenheimer on November 15, 2023. The analyst firm set a price target for $25.00 expecting ATXS to rise to within 12 months (a possible 433.05% upside). 11 analyst firms have reported ratings in the last year.
奥本海默于2023年11月15日公布了Astria Therapeutics（纳斯达克股票代码：ATXS）的最新目标股价。该分析公司将目标股价定为25.00美元，预计ATXS将在12个月内升至12个月内（可能上涨433.05％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Astria Therapeutics (ATXS)?
分析师对Astria Therapeutics（ATXS）的最新评级是多少？
The latest analyst rating for Astria Therapeutics (NASDAQ: ATXS) was provided by Oppenheimer, and Astria Therapeutics maintained their outperform rating.
奥本海默对Astria Therapeutics（纳斯达克股票代码：ATXS）的最新分析师评级由奥本海默提供，Astria Therapeutics维持跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Astria Therapeutics (ATXS)?
Astria Therapeutics（ATXS）的下一次分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Astria Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Astria Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Astria Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Astria Therapeutics的最新评级是在2023年11月15日公布的，因此您应该预计下一个评级将在2024年11月15日左右公布。
Is the Analyst Rating Astria Therapeutics (ATXS) correct?
分析师对Astria Therapeutics（ATXS）的评级是否正确？
While ratings are subjective and will change, the latest Astria Therapeutics (ATXS) rating was a maintained with a price target of $30.00 to $25.00. The current price Astria Therapeutics (ATXS) is trading at is $4.69, which is out of the analyst's predicted range.
尽管评级是主观的，而且会发生变化，但最新的Astria Therapeutics（ATXS）评级维持不变，目标股价为30美元至25.00美元。Astria Therapeutics（ATXS）目前的交易价格为4.69美元，超出了分析师的预期区间。
译文内容由第三方软件翻译。